KRT17 and triple-negative breast carcinoma: The expression rate of KRT17 in triple-negative breast cancer exceeds 80%, whereas the expression rate in non-TNBC is less than 50%, and its expression is positively correlated with poor breast cancer prognosis (Merkin et al. 2017).